Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

68.41 +1.11 (+1.65%)
Streaming Delayed Price Updated: 10:47 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,802,928
Open 68.04
Bid (Size) 68.40 (84)
Ask (Size) 68.41 (15)
Prev. Close 67.30
Today's Range 67.92 - 68.63
52wk Range 61.24 - 87.67
Shares Outstanding N/A
Dividend Yield 3.07%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens
The company noted that no new safety concerns were identified with the combination of Imfinzi and BCG induction and maintenance therapy in the trial. 
Via Stocktwits
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
From AstraZeneca
Via Business Wire

Performance

YTD
+3.8%
+3.8%
1 Month
+5.3%
+5.3%
3 Month
-5.5%
-5.5%
6 Month
+5.8%
+5.8%
1 Year
-11.1%
-11.1%

More News

Read More
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Via Benzinga
Topics ETFs Government
Exposures Political
What Does the Market Think About AstraZeneca?
Via Benzinga
Earnings Scheduled For April 29, 2025
Via Benzinga
Tempus AI Stock: Time to Double Down or Cut and Run?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
From AstraZeneca
Via Business Wire
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
AstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment Dips
Via Stocktwits
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
Via Benzinga
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s Positive
Via Stocktwits
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
From AstraZeneca
Via Business Wire
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty
Via Benzinga
AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops
Via Investor's Business Daily
Topics Earnings Government
Exposures Financial Political Product Safety
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
Via Benzinga
AstraZeneca's Q1 2025 Financial Results
From AstraZeneca
Via Business Wire
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Via Talk Markets
Topics ETFs Stocks / Equities
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Via MarketBeat
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
From AstraZeneca
Via Business Wire
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 68.41
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 05/09/25 10:47 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.